  Background: Depression in people with bipolar disorder is a major cause of
long-term disability, possibly leading to early mortality and currently,
limited safe and effective therapies exist. A double-blinded randomized
placebo-controlled trial (CEQUEL study) was conducted to evaluate the efficacy
of Lamotrigine plus Quetiapine versus Quetiapine monotherapy in patients with
bipolar type I or type II disorders.
  Objective: The objective of our study was to reanalyze CEQUEL data and
determine an unbiased classification accuracy for active lamotrigine versus
placebo. We also wanted to establish the time it took for the drug to provide
statistically significant outcomes.
  Methods: Between October 21, 2008 and April 27, 2012, 202 participants from
27 sites in United Kingdom were randomly assigned to two treatments; 101:
lamotrigine, 101: placebo. The primary variable used for estimating depressive
symptoms was based on the Quick Inventory of Depressive Symptomatology-self
report version 16 (QIDS-SR16). We analyze the data using feature engineering
and simple classifiers.
  Results: From weeks 10 to 14, the mean difference in QIDS-SR16 ratings
between the groups was -1.6317 (P=.09; sample size=81, 77; 95% CI -0.2403 to
3.5036). From weeks 48 to 52, the mean difference was -2.0032 (P=.09; sample
size=54, 48; 95% CI -0.3433 to 4.3497). The coefficient of variation and
detrended fluctuation analysis (DFA) exponent alpha had the greatest
explanatory power. The out-of-sample classification accuracy for the 138
participants who reported more than 10 times after week 12 was 62%. A
consistent classification accuracy higher than the no-information benchmark was
obtained in week 44.
  Conclusions: Lamotrigine plus Quetiapine treatment decreased depressive
symptoms in patients, but with substantial temporal instability. A trial of at
least 44 weeks was required to achieve consistent results.
